Next Article in Journal
DNA Methylation Profiling of Human Prefrontal Cortex Neurons in Heroin Users Shows Significant Difference between Genomic Contexts of Hyper- and Hypomethylation and a Younger Epigenetic Age
Next Article in Special Issue
The Dual Roles of MYC in Genomic Instability and Cancer Chemoresistance
Previous Article in Journal
Reticulate Evolution of the Rock Lizards: Meiotic Chromosome Dynamics and Spermatogenesis in Diploid and Triploid Males of the Genus Darevskia
Previous Article in Special Issue
MYC—Master Regulator of the Cancer Epigenome and Transcriptome
Open AccessReview

MYC Deregulation in Primary Human Cancers

Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 1L7, Canada
Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada
Sunnybrook Research Institute, Toronto, ON M4N 3M5, Canada
Author to whom correspondence should be addressed.
Academic Editor: Daitoku Sakamuro
Genes 2017, 8(6), 151;
Received: 23 March 2017 / Revised: 19 May 2017 / Accepted: 19 May 2017 / Published: 25 May 2017
(This article belongs to the Special Issue MYC Networks)
MYC regulates a complex biological program by transcriptionally activating and repressing its numerous target genes. As such, MYC is a master regulator of many processes, including cell cycle entry, ribosome biogenesis, and metabolism. In cancer, the activity of the MYC transcriptional network is frequently deregulated, contributing to the initiation and maintenance of disease. Deregulation often leads to constitutive overexpression of MYC, which can be achieved through gross genetic abnormalities, including copy number alterations, chromosomal translocations, increased enhancer activity, or through aberrant signal transduction leading to increased MYC transcription or increased MYC mRNA and protein stability. Herein, we summarize the frequency and modes of MYC deregulation and describe both well-established and more recent findings in a variety of cancer types. Notably, these studies have highlighted that with an increased appreciation for the basic mechanisms deregulating MYC in cancer, new therapeutic vulnerabilities can be discovered and potentially exploited for the inhibition of this potent oncogene in cancer. View Full-Text
Keywords: MYC; deregulation; cancer; gene amplification; translocation; enhancers; cell signaling MYC; deregulation; cancer; gene amplification; translocation; enhancers; cell signaling
Show Figures

Figure 1

MDPI and ACS Style

Kalkat, M.; De Melo, J.; Hickman, K.A.; Lourenco, C.; Redel, C.; Resetca, D.; Tamachi, A.; Tu, W.B.; Penn, L.Z. MYC Deregulation in Primary Human Cancers. Genes 2017, 8, 151.

AMA Style

Kalkat M, De Melo J, Hickman KA, Lourenco C, Redel C, Resetca D, Tamachi A, Tu WB, Penn LZ. MYC Deregulation in Primary Human Cancers. Genes. 2017; 8(6):151.

Chicago/Turabian Style

Kalkat, Manpreet; De Melo, Jason; Hickman, Katherine A.; Lourenco, Corey; Redel, Cornelia; Resetca, Diana; Tamachi, Aaliya; Tu, William B.; Penn, Linda Z. 2017. "MYC Deregulation in Primary Human Cancers" Genes 8, no. 6: 151.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop